Introduction: The Shift Toward Value-Based IBD Care

Biologic therapies have revolutionized the management of inflammatory bowel disease, but their high cost remains a significant barrier for many patients. Recent research published in the Journal of Medical Economics highlights how infliximab biosimilar Crohn's disease treatment protocols offer a sustainable alternative to the bio-originator. This retrospective study evaluated 473 adult patients in China to compare the clinical outcomes and economic impact of originator infliximab (O-IFX) versus its biosimilar (B-IFX).

Clinical Equivalence in Real-World Settings

The study found that clinical endpoints over a 12-month period were comparable between both groups. Specifically, rates of treatment failure, clinical remission, and endoscopic response showed no significant statistical differences. Furthermore, safety profiles remained consistent, with adverse event rates being similar for patients using either the originator or the biosimilar. Consequently, clinicians can feel confident that transitioning to biosimilars does not compromise patient safety or therapeutic efficacy.

The Economic Impact of Infliximab Biosimilar Crohn's Disease Adoption

From a healthcare payer perspective, the adoption of biosimilars presents a compelling financial case. Researchers performed a budget impact analysis for the 2025-2027 period, projecting that increased biosimilar uptake could save approximately 3.44 million CNY (Chinese Yuan). Sensitivity analyses revealed that the unit price of the originator drug is the primary cost driver. Nevertheless, the biosimilar remained cost-saving across all tested parameters. These findings suggest that broader adoption is a viable strategy for improving the sustainability of medical insurance funds.

Conclusion: Enhancing Affordability and Access

The evidence supports the use of biosimilars as a value-based strategy to enhance the affordability of biologic therapy. By providing similar clinical outcomes at a fraction of the cost, these agents help healthcare systems maintain high-quality care while managing rising pharmaceutical expenditures. Therefore, medical professionals and policymakers should consider biosimilars as a primary option for long-term Crohn’s disease management.

Frequently Asked Questions

Is switching from an originator to an infliximab biosimilar safe for Crohn’s disease patients?

Yes, real-world data and numerous studies indicate that switching to an infliximab biosimilar Crohn's disease treatment is safe and does not lead to increased adverse events or loss of clinical efficacy.

How much can healthcare systems save by adopting biosimilars?

Savings vary by region, but this specific study estimated cumulative savings of 3.44 million CNY over three years for a single tertiary center's cohort, highlighting the massive potential for national healthcare systems.

Are the remission rates the same for biosimilars and originators?

Clinical studies show that remission rates and endoscopic responses are comparable between biosimilars and originators, meaning patients can expect the same level of disease control.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Shi J et al. Real-world clinical, safety, and economic evaluation of infliximab biosimilar adoption for crohn's disease. J Med Econ. 2026 Dec undefined. doi: 10.1080/13696998.2026.2642555. PMID: 41811347.

Oike T et al. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn's disease. Arab J Gastroenterol. 2024 Aug;25(3):257-262. doi: 10.1016/j.ajg.2024.03.006.

Severs M et al. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):289-296. doi: 10.1093/ecco-jcc/jjw153.